- Comprehensive meta analysis software for mac for mac#
- Comprehensive meta analysis software for mac software#
- Comprehensive meta analysis software for mac trial#
Results: After reviewing 3665 records, we identified 24 studies that satisfied the inclusion criteria. We considered P <0.05 as statistically significant for publication bias. The pooled frequency with 95% confidence intervals (CI) was assessed using a random-effect model.
Comprehensive meta analysis software for mac software#
Statistical analyses were performed with Comprehensive Meta-Analysis Software Version 2.0 (Biostat, Englewood, NJ).
Methods: We reviewed the relevant scientific literature published up to February 18, 2020.
Comprehensive meta analysis software for mac for mac#
Although current guidelines recommend initial therapy for MAC with rifampin, it has been theorized to be less efficacious than rifabutin. MAC's standard treatment regimen includes a macrolide, ethambutol, and a rifamycin, among which rifampin and rifabutin are the most commonly used. N2 - Background: The incidence of Mycobacterium avium complex (MAC) increases as immunosuppressed conditions become more common. © Copyright © 2021 Hajikhani, Nasiri, Adkinson, Azimi, Khalili, Goudarzi, Dadashi, Murthi and Mirsaeidi. T1 - Comparison of Rifabutin-Based Versus Rifampin-Based Regimens for the Treatment of Mycobacterium avium Complex
Comprehensive meta analysis software for mac trial#
In order to determine the exact preference of each of these drugs, double-blind clinical trial studies are recommended.", Conclusion: In this study, it was shown that in comparison to Rifabutin, rifampin has similar treatment success rates in treating MAC. There was no evidence of publication bias among the included studies (Eggers test p-value was 0.7). The estimated pooled treatment success rate was found to be 54.7% (95% CI 41.0-67.0%) in rifabutin groups and 67.5% (95% CI 55.7-77.4%) in rifampin groups. Among these studies, 8 had rifabutin in their regimens (rifabutin group) and 16 had rifampin in their regimens (rifampin group).
In order to determine the exact preference of each of these drugs, double-blind clinical trial studies are recommended.Ībstract = "Background: The incidence of Mycobacterium avium complex (MAC) increases as immunosuppressed conditions become more common. There was no evidence of publication bias among the included studies (Egger’s test p-value was 0.7).
Background: The incidence of Mycobacterium avium complex (MAC) increases as immunosuppressed conditions become more common.
0 kommentar(er)
